Correction: SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

Código QR

Correction: SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

Guardado en:

Detalles Bibliográficos
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2f9adcb060bb4071b3c13a6fe4711307
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
por: Paolo Antonio Ascierto, et al.
Publicado: (2021)

Correction: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
Publicado: (2021)

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
por: Tomas G Neilan, et al.
Publicado: (2021)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Zheng-Hang Wang, et al.
Publicado: (2018)

Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
por: Marina A. Lyadova, et al.
Publicado: (2021)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
por: Zoe Apalla, et al.
Publicado: (2021)

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
por: Rilan Bai, et al.
Publicado: (2021)

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
por: Kennedy Yao Yi Ng, et al.
Publicado: (2021)

Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Despina Michailidou, et al.
Publicado: (2021)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Xiaoyin Bai, et al.
Publicado: (2021)

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion
por: David Simon, et al.
Publicado: (2020)

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
por: Nuttapong Ngamphaiboon, et al.
Publicado: (2021)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Di Wang, et al.
Publicado: (2021)

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
por: Ying Jing, et al.
Publicado: (2020)

Correction to: Clinical, radiological and functional outcomes in patients with SARS-CoV-2 pneumonia: a prospective observational study
por: Pietro Gianella, et al.
Publicado: (2021)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: Rosaria De Filippi, et al.
Publicado: (2021)

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
por: Ke Cheng, et al.
Publicado: (2021)

SARS-CoV-2 Infection and C-Section: A Prospective Observational Study
por: Eva Morán Antolín, et al.
Publicado: (2021)

Author Correction: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
por: Xiuyuan Ou, et al.
Publicado: (2021)

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines
por: Francesco Bellinato, et al.
Publicado: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou W, et al.
Publicado: (2021)

Correction: Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
Publicado: (2021)

Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity
por: Hagit Achdout, et al.
Publicado: (2021)

Comparison of the Characteristics of Cytokine Storm and Immune Response Induced by SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections
por: Liu T, et al.
Publicado: (2021)

Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
por: Anne R Bass, et al.
Publicado: (2021)

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
por: Kun-Hsing Yu, et al.
Publicado: (2021)

Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Sho Iketani, et al.
Publicado: (2021)

Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study.
por: Marije S Koks, et al.
Publicado: (2021)

Author Correction: Genomic recombination events may reveal the evolution of coronavirus and the origin of SARS-CoV-2
por: Zhenglin Zhu, et al.
Publicado: (2021)

Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
por: Feicheng Wang, et al.
Publicado: (2021)

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
por: Xiuyuan Ou, et al.
Publicado: (2020)

Investigation of Thiocarbamates as Potential Inhibitors of the SARS-CoV-2 Mpro
por: Katarzyna Papaj, et al.
Publicado: (2021)

Household transmission of SARS-CoV-2: a prospective observational study in Bosnia and Herzegovina, August–December 2020
por: Sanjin Musa, et al.
Publicado: (2021)

Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects
por: Varahachalam SP, et al.
Publicado: (2021)

Indicators of responsiveness to immune checkpoint inhibitors
por: Bradley D. Shields, et al.
Publicado: (2017)

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
por: Xiujing He, et al.
Publicado: (2021)

Correction: Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
por: Shawn T. Beug, et al.
Publicado: (2018)

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
por: Michael Dougan, et al.
Publicado: (2021)

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
por: Donal T. Skelly, et al.
Publicado: (2021)

Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase
por: Syed Hani Abidi, et al.
Publicado: (2021)